The State Board of Pharmacy met earlier this week and although the meeting was short there are a number of important items that were discussed. The Compounding Task Force reported on a few items including Office-use Compounding. The Board provided a Memorandum that addressed the issue. The memorandum titled Consideration of Proposed Standards for Office-Use Compounding, stated, "There is a question of whether the Division should allow a pharmacy to sell compounded medications to a practitioner for office-use without a patient-specific prescription...At the July Board meetings, Board members recommended that the Division adopt rules allowing this practice; however since that meeting the Division was informed by representatives of the Food and Drug Administration that a pharmacy could comply with the office use compounding standards outlined in the Utah Administrative Code but be fined or cited by the FDA for failure to comply with the Drug Quality and security act. The State Board will be sending an official letter to the FDA to hopefully get a better clarification on the issue.
The Board has also reviewed the rule progress of SB 55 rule making. Although the rules are not complete yet, it is anticipated that it should be near completion this fall. UPhA has been heavily involved in this process to be sure that the integrity of the pharmacy act rules are kept in tack. UPhA has also been noting areas of the rule that need further or changing. UPhA anticipates over the next year, a full review of both the Pharmacy Practice Act and Rules.
Positive identification was also discussed and this has been addressed on a national level with certain national organizations. The question raised is what is the definition of "positive identification." Most national organizations have noted this to be a government issued i.d. The Board will be working to create an inclusive and exclusive list of i.d.'s. Look for that list in the next couple months.
The next State Board of Pharmacy meeting will be September 23rd. Also for a full recording of the meeting visit the DOPL website or click here.